WebMD Global requires every individual in a position to control educational content to disclose all financial relationships
with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary
business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed
below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with
ineligible companies.
Disclosures for additional planners can be found here.
Faculty
-
Arshad M. Khanani, MD, MA, FARS
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Director of Clinical Research
Sierra Eye Associates
Reno, Nevada, United States
Disclosures
Arshad M. Khanani, MD, MA, FARS, has the following relevant financial relationships:
Consultant or advisor for: 4DMT; Adverum; Alimera Sciences; Allergan, Inc.; Apellis Pharmaceuticals; Asclepix; Aviceda; Bausch
& Lomb Inc.; Broadwing Bio; Chengdu Kanghong; Cholgene; Dutch Ophthalmic Research Center; Gemini; Genentech, Inc.; Glaukos
Corporation; Graybug Vision, Inc.; Gyroscope; Iveric Bio; Janssen Biotech, Inc.; Kato Pharma; Kodiak Sciences; Novartis; Oculis;
Opthea; Oxurion; Polyphotonix; Recens Medical; Regeneron Pharmaceuticals, Inc.; Regenxbio; Retrotope; RevOpsis; Roche; Thea;
Unity Bio
Speaker or member of speakers bureau for: Allergan, Inc.; Genentech, Inc.; Novartis
Research funding from: 4DMT; Adverum; Apellis Pharmaceuticals; Asclepix; Chengdu Kanghong; Gemini; Genentech, Inc.; Graybug
Vision, Inc.; Gyroscope; Iveric Bio; Kodiak Sciences; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis; Ocular
Therapeutix; Oculis; Opthea; Oxurion; Recens Medical; Regenxbio; Roche; Unity Bio
Stock options from: Aviceda; Polyphotonix; Recens Medical; Retrotope
-
Dante J. Pieramici, MD
Partner, California Retina Consultants
Director, California Retina Research Foundation,
Santa Barbara, California, United States
Disclosures
Dante J. Pieramici, MD, has the following relevant financial relationships:
Consultant or advisor for: Adverum; Arrowhead Pharmaceuticals, Inc.; Gemini; Genentech, Inc.; NGM Biopharmaceuticals; Opthea;
Regeneron Pharmaceuticals, Inc.; Regenxbio; Unity Bio
Research funding from: 4DMT; Adverum; Apellis Pharmaceuticals; Clearside; Genentech, Inc.; Kodiak Sciences; Ocular Therapeutix;
Opthea; Regenxbio; Stealth BioTherapeutics Inc.;
Editor
Compliance Reviewer
Peer Reviewer
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
